朱力先生自2010加入金斯瑞生物至今，先后担任金斯瑞集团公司商务发展副总裁和首席战略官。参加过2015年金斯瑞在香港主版上市的准备工作和2017年传奇生物跟Jenssen高达3.5亿美元首付款的BCMA-CART细胞治疗项目license and co-development合作项目的谈判。

朱先生1990-2000在美国Clontech公司工作，先后担任Research Scientist，Group Leader，Director of Molecular Biology Division；2000-2006在美国自行创办Genetastix公司，担任President and CEO；2006-2009在上海凯赛生物担任研发副总裁。

朱先生1982上海华东师范大学生物学本科毕业，1989获得美国斯坦福大学分子生物学博士学位。朱力博士曾在加州大学伯克利分校进修商务课程获得结业证书。

Li ZHU

Chief Strategy Officer of GenScript

Dr. Li Zhu is Chief Strategy Officer of GenScript. He leads new business development. Li obtained his bachelor degree in China in 1982 and his PhD degree at Stanford University in molecular biology and immunology in 1989. He worked at Clontech Laboratories in California from 1990 to 2000, successfully pioneered the commercialization of yeast two-hybrid system and a series of other advanced molecular biology techniques. He founded and managed Genetastix, a platform biotech company focusing on creating human antibody library in yeast and screening such library with genetic method. He returned to China in 2006 and worked at two biotech companies in Shanghai Zhangjiang High-tech Park before joining GenScript in 2010.

At GenScript, he has been in charge of corporate business development, focusing on new business opportunity identification, negotiation, deal-making, and external business relationship maintenance. He actively participated in new technology and IP in-licensing. Immediately after Legend disclosed early successful clinical study result on relapsed and refractory multiple myeloma patients at 2017 ASCO conference in Chicago, he led the business contact with a number of major global top pharmaceutical companies, made site visits and coordinated follow up contacts and negotiations, and participated in the 2-month-long intense negotiation along with top GenScript executive team with Jenssen executives in Nanjing and in New Jersey, and finally concluded the landmark license and co-development agreement by the end of 2017 with Jenssen.